Sanofi SA banner

Sanofi SA
OTC:SNYNF

Watchlist Manager
Sanofi SA Logo
Sanofi SA
OTC:SNYNF
Watchlist
Price: 92.44 USD Market Closed
Market Cap: $115.9B

EV/S

1.8
Current
36%
Cheaper
vs 3-y average of 2.8

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
1.8
=
Enterprise Value
$105.4B
/
Revenue
€58B

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
1.8
=
Enterprise Value
$105.4B
/
Revenue
€58B

Valuation Scenarios

Sanofi SA is trading below its 3-year average

If EV/S returns to its 3-Year Average (2.8), the stock would be worth $144.21 (56% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-21%
Maximum Upside
+58%
Average Upside
19%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 1.8 $92.44
0%
3-Year Average 2.8 $144.21
+56%
5-Year Average 2.9 $145.92
+58%
Industry Average 1.5 $78.63
-15%
Country Average 1.4 $72.99
-21%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
$105.4B
/
Apr 2026
€58B
=
1.8
Current
$105.4B
/
Dec 2026
€48.3B
=
2.2
Forward
$105.4B
/
Dec 2027
€51.3B
=
2.1
Forward
$105.4B
/
Dec 2028
€53.9B
=
2
Forward
$105.4B
/
Dec 2029
€55.2B
=
1.9
Forward
$105.4B
/
Dec 2030
€57.3B
=
1.8
Forward
$105.4B
/
Dec 2031
€55.9B
=
1.9
Forward
$105.4B
/
Dec 2032
€49.8B
=
2.1
Forward
$105.4B
/
Dec 2033
€46B
=
2.3
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close

Market Distribution

In line with most companies in France
Percentile
61st
Based on 1 736 companies
61st percentile
2.1
Low
0 — 0.8
Typical Range
0.8 — 2.8
High
2.8 —
Distribution Statistics
France
Min 0
30th Percentile 0.8
Median 1.4
70th Percentile 2.8
Max 29 441 857.7

Sanofi SA
Glance View

Sanofi SA, a titan in the global healthcare sector, operates at the intricate crossroads of pharmaceutical innovation and patient care, driven by an unyielding commitment to improving human health. Emerging from its French roots, Sanofi has strategically positioned itself as a global leader in pharmaceuticals, vaccines, and consumer healthcare. The company’s success is essentially anchored in its capacity to consistently develop and commercialize life-saving drugs that address a myriad of health concerns, ranging from diabetes and cardiovascular diseases to rare disorders and oncology. Underlining its robust revenue engine is Sanofi's extensive R&D infrastructure that fuels its pipeline with groundbreaking therapies, reflecting a dynamic blend of scientific acumen and market-focused agility. By leveraging a hybrid model that integrates cutting-edge research with strategic alliances and acquisitions, Sanofi ensures a sustained presence in the highly competitive biopharmaceutical landscape. Enabling this network of innovation and impact is Sanofi's diverse portfolio, a balanced mix of specialty and established prescription drugs, over-the-counter products, and the critical arm of vaccines led by its Sanofi Pasteur division. This diversification offers both growth opportunities and stability, cushioning against the volatile tides of patent expirations and regulatory changes. Its vaccines segment, in particular, is a cornerstone in Sanofi's business, capturing substantial market share with products critical to global immunization efforts, further amplified by its role in responding to health emergencies like the COVID-19 pandemic. With a geographically expansive sales footprint and strategic marketing strategies, Sanofi capitalizes on emerging market opportunities while maintaining a strong presence in established regions, effectively making its bottom line a testimony to its operational excellence and strategic foresight in harmonizing science with humanity.

SNYNF Intrinsic Value
183.93 USD
Undervaluation 50%
Intrinsic Value
Price $92.44
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett